Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 6/2022

01-06-2022 | Shingles | Review Article

Ulcerative Colitis in Adulthood and in Older Patients: Same Disease, Same Outcome, Same Risks?

Authors: Walter Fries, Maria Giulia Demarzo, Giuseppe Navarra, Anna Viola

Published in: Drugs & Aging | Issue 6/2022

Login to get access

Abstract

The number of patients with inflammatory bowel disease (IBD) approaching an older age, together with the number of over-60-year-old patients newly diagnosed with IBD, is steadily increasing, reaching 25% of all patients. The present review focuses on late-onset ulcerative colitis (UC) and its initial disease course in comparison with that observed in younger adults in terms of extension at onset and the risk of proximal disease progression, medical treatment, surgery and hospitalization in the first years after diagnosis. We summarize the clues pointing to a milder disease course in a population which frequently presents major frailty due to comorbidities. With increasing age and thus increasing comorbidities, medical and surgical therapies frequently represent a challenge for treating physicians. The response, persistence, and risks of adverse events of conventional therapies indicated for late onset/older UC patients are examined, emphasizing the risks in this particular population, who are still being treated with prolonged corticosteroid therapy. Finally, we concentrate on data on biotechnological agents for which older patients were mostly excluded from pivotal trials. Real-life data from newer agents such as vedolizumab and ustekinumab show encouraging efficacy and safety profiles in the population of older UC patients.
Literature
1.
Keyashian K, Dehghan M, Sceats L, Kin C, Limketkai BN, Park KT. Comparative incidence of inflammatory bowel disease in different age groups in the United States. Inflamm Bowel Dis. 2019;25:1983–9.PubMedPubMedCentralCrossRef
2.
Nørgård BM, Nielsen J, Fonager K, Kjeldsen J, Jacobsen BA, Qvist N. The incidence of ulcerative colitis (1995–2011) and Crohn’s disease (1995–2012) - based on nationwide Danish registry data. J Crohns Colitis. 2014;8:1274–80.PubMedCrossRef
3.
Jeuring SF, van den Heuvel TR, Zeegers MP, Hameeteman WH, Romberg-Camps MJ, Oostenbrug LE, et al. Epidemiology and long-term outcome of inflammatory bowel disease diagnosed at elderly age-an increasing distinct entity? Inflamm Bowel Dis. 2016;22:1425–34.PubMedCrossRef
4.
Everhov ÅH, Halfvarson J, Myrelid P, Sachs MC, Nordenvall C, Söderling J, et al. Incidence and treatment of patients diagnosed with inflammatory bowel diseases at 60 years or older in Sweden. Gastroenterology. 2018;154:518–28.PubMedCrossRef
5.
Coward S, Clement F, Benchimol EI, Bernstein CN, Avina-Zubieta JA, Bitton A, et al. Past and future burden of inflammatory bowel diseases based on modeling of population-based data. Gastroenterology. 2019;156:1345–53.PubMedCrossRef
6.
Riegler G, Tartaglione MT, Carratú R, D’Incá R, Valpiani D, Russo MI, et al. Age-related clinical severity at diagnosis in 1705 patients with ulcerative colitis: a study by GISC (Italian Colon-Rectum Study Group). Dig Dis Sci. 2000;45:462–5.PubMedCrossRef
7.
Greth J, Török HP, Koenig A, Folwaczny C. Comparison of inflammatory bowel disease at younger and older age. Eur J Med Res. 2004;9:552–4.PubMed
8.
Gower-Rousseau C, Vasseur F, Fumery M, Savoye G, Salleron J, Dauchet L, et al. Epidemiology of inflammatory bowel diseases: new insights from a French population-based registry (EPIMAD). Dig Liver Dis. 2013;45:89–94.PubMedCrossRef
9.
Charpentier C, Salleron J, Savoye G, Fumery M, Merle V, Laberenne JE, et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut. 2014;63:423–32.PubMedCrossRef
10.
Hadithi M, Cazemier M, Meijer GA, Bloemena E, Felt-Bersma RJ, Mulder CJ, et al. Retrospective analysis of old-age colitis in the Dutch inflammatory bowel disease population. World J Gastroenterol. 2008;14:3183–7.PubMedPubMedCentralCrossRef
11.
12.
13.
Burgmann T, Clara I, Graff L, Walker J, Lix L, Rawsthorne P, et al. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis–how much is irritable bowel syndrome? Clin Gastroenterol Hepatol. 2006;4:614–20.PubMedCrossRef
14.
Ananthakrishnan AN, Shi HY, Tang W, Law CC, Sung JJ, Chan FK, Ng SC. Systematic review and meta-analysis: phenotype and clinical outcomes of older-onset inflammatory bowel disease. J Crohns Colitis. 2016;10:1224–36.PubMedPubMedCentralCrossRef
15.
Fries W, Viola A, Manetti N, Frankovic I, Pugliese D, Monterubbianesi R, et al. Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD “AGED study.” Dig Liver Dis. 2017;49:17–23.PubMedCrossRef
16.
Kumar V, Shah Y, Patel D, Khan N. Elderly-onset and adult-onset ulcerative colitis are more similar than previously reported in a nationwide cohort. Dig Dis Sci. 2017;62:2857–62.PubMedCrossRef
17.
Mañosa M, Calafat M, de Francisco R, García C, Casanova MJ, Huelín P, et al. GETECCU. Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study. Aliment Pharmacol Ther. 2018;47:605–14.PubMedCrossRef
18.
Hou JK, Feagins LA, Waljee AK. Characteristics and behavior of elderly-onset inflammatory bowel disease: a multi-center US study. Inflamm Bowel Dis. 2016;22:2200–5.PubMedCrossRef
19.
Mak JWY, Ho CLT, Wong K, Cheng TY, Yip TCF, Leung WK, et al. Epidemiology and natural history of elderly-onset inflammatory bowel disease: results from a territory-wide Hong Kong IBD registry. J Crohns Colitis. 2020;15:401–8.CrossRef
20.
Park SH, Jeong SK, Lee JH, Rhee KH, Kim YH, Hong SN, et al. Songpa-Kangdong Inflammatory Bowel Disease (SK-IBD) Study Group. Clinical characteristics and long-term prognosis of elderly-onset ulcerative colitis in a population-based cohort in the Songpa-Kangdong district of Seoul, Korea. Gut Liver. 2021;15:742–51.PubMedPubMedCentralCrossRef
21.
Ha CY, Newberry RD, Stone CD, Ciorba MA. Patients with late-adult-onset ulcerative colitis have better outcomes than those with early onset disease. Clin Gastroenterol Hepatol. 2010;8:682–7.PubMedPubMedCentralCrossRef
22.
Lakatos PL, David G, Pandur T, Erdelyi Z, Mester G, Balogh M, et al. IBD in the elderly population: results from a population-based study in Western Hungary, 1977–2008. J Crohns Colitis. 2011;5:5–13.PubMedCrossRef
23.
Softley A, Myren J, Clamp SE, Bouchier IA, Watkinson G, de Dombal FT. Inflammatory bowel disease in the elderly patient. Scand J Gastroenterol. 1988;23(Suppl. 144):27–30.
24.
Kochar B, Jylhävä J, Söderling J, Ritchie CS, Ludvigsson JF, Khalili H, Olén O. SWIBREG Study Group. Prevalence and implications of frailty in older adults with incident inflammatory bowel diseases: a nationwide cohort study. Clin Gastroenterol Hepatol. 2022;S1542–3565(22):00007–16.
25.
Nguyen GC, Sheng L, Benchimol EI. Health care utilization in elderly onset inflammatory bowel disease: a population-based study. Inflamm Bowel Dis. 2015;21:777–82.PubMedCrossRef
26.
Ko MK, Ng SC, Mak LY, Li MK, Lo FH, Ng CK, et al. Infection-related hospitalizations in the first year after inflammatory bowel disease diagnosis. Dig Dis. 2016;17:610–7.CrossRef
27.
Ananthakrishnan AN, McGinley EL, Binion DG. Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm Bowel Dis. 2009;15:182–9.PubMedCrossRef
28.
Nguyen GC, Bollegala N, Chong CA. Factors associated with readmissions and outcomes of patients hospitalized for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;12:1897–904.PubMedCrossRef
29.
Nguyen GC, Bernstein CN, Benchimol EI. Risk of surgery and mortality in elderly-onset inflammatory bowel disease: a population-based cohort study. Inflamm Bowel Dis. 2017;23:218–23.PubMedCrossRef
30.
Targownik LE, Singh H, Nugent Z, Bernstein CN. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol. 2012;107:1228–35.PubMedCrossRef
31.
Shimodaira Y, Watanabe K, Iijima K. Clinical course of ulcerative colitis associated with an age at diagnosis: a recent Japanese Database Survey. Tohoku J Exp Med. 2021;255:33–9.PubMedCrossRef
32.
Bewtra M, Newcomb CW, Wu Q, Chen L, Xie F, Roy JA, et al. Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study. Ann Intern Med. 2015;163:262–70.PubMedPubMedCentralCrossRef
33.
Isene R, Bernklev T, Høie O, Munkholm P, Tsianos E, Stockbrügger R, et al. EC-IBD Study Group. Extraintestinal manifestations in Crohn’s disease and ulcerative colitis: results from a prospective, population-based European inception cohort. Scand J Gastroenterol. 2015;50:300–5.PubMedCrossRef
34.
Kochar B, Kalasapudi L, Ufere NN, Nipp RD, Ananthakrishnan AN, Ritchie CS. Systematic review of inclusion and analysis of older adults in randomized controlled trials of medications used to treat inflammatory bowel diseases. Inflamm Bowel Dis. 2021;27:1541–3.PubMedCrossRef
35.
Parian A, Ha CY. Older age and steroid use are associated with increasing polypharmacy and potential medication interactions among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2015;21:1392–400.PubMed
36.
Okabayashi S, Yamazaki H, Tominaga K, Miura M, Sagami S, Matsuoka K, et al. IBD Terakoya Group. Lower effectiveness of intravenous steroid treatment for moderate-to-severe ulcerative colitis in hospitalised patients with older onset: a multicentre cohort study. Aliment Pharmacol Ther. 2022. https://​doi.​org/​10.​1111/​apt.​16865.CrossRefPubMed
37.
38.
Juneja M, Baidoo L, Schwartz MB, Barrie A, Regueiro M, Dunn M, Binion DG. Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity. Dig Dis Sci. 2012;57:2408–15.PubMedCrossRef
39.
Song EM, Lee HS, Park SH, Kim GU, Seo M, Hwang SW, et al. Clinical characteristics and long-term prognosis of elderly onset ulcerative colitis. J Gastroenterol Hepatol. 2018;33:172–9.PubMedCrossRef
40.
Calafat M, Mañosa M, Mesonero F, Guardiola J, Mínguez M, Nos P, et al. ENEIDA registry of GETECCU. Switching to a second thiopurine in adult and elderly patients with inflammatory bowel disease: a nationwide study from the ENEIDA Registry. J Crohns Colitis. 2020;14:1290–8.PubMedCrossRef
41.
Chan W, Kariyawasam VC, Kim S, Pudipeddi AV, Paramsothy S, Shim HH, et al. Gastroenterologists’ preference and risk perception on the use of immunomodulators and biological therapies in elderly patients with ulcerative colitis: as international survey. Eur J Gastroenterol Hepatol. 2020;32:976–83.PubMedCrossRef
42.
Kariyawasam VC, Kim S, Mourad FH, Selinger CP, Katelaris PH, Brian Jones D, et al. Comorbidities rather than age are associated with the use of immunomodulators in elderly-onset infammatory bowel disease. Inflamm Bowel Dis. 2019;25:1390–8.PubMedCrossRef
43.
Alexakis C, Saxena S, Chhaya V, Cecil E, Curcin V, Pollok R. Do thiopurines reduce the risk of surgery in elderly onset inflammatory bowel disease? A 20-year national population-based cohort study. Inflamm Bowel Dis. 2017;23:672–80.PubMedCrossRef
44.
Calafat M, Mañosa M, Cañete F, Ricart E, Iglesias E, Calvo M, et al. ENEIDA registry of GETECCU. Increased risk of thiopurine-related adverse events in elderly patients with IBD. Aliment Pharmacol Ther. 2019;50:780–8.PubMedCrossRef
45.
Geisz M, Ha C, Kappelman MD, Martin CF, Chen W, Anton K, Sandler RS, Long MD. Medication utilization and the impact of continued corticosteroid use on patient-reported outcomes in older patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:1435–41.PubMedCrossRef
46.
Moroi R, Shiga H, Tarasawa K, Yano K, Shimoyama Y, Kuroha M, Kakuta Y, Fushimi K, Fujimori K, Kinouchi Y, Masamune A. The clinical practice of ulcerative colitis in elderly patients: an investigation using a nationwide database in Japan. JGH Open. 2021;5:842–8.PubMedPubMedCentralCrossRef
47.
Amano T, Shinzaki S, Asakura A, Tashiro T, Tani M, Otake Y, et al. Elderly onset age is associated with low efficacy of first anti-tumor necrosis factor treatment in patients with inflammatory bowel disease. Sci Rep. 2022;12(1):5324.PubMedPubMedCentralCrossRef
48.
Cheng D, Cushing KC, Cai T, Ananthakrishnan AN. Safety and efficacy of tumor necrosis factor antagonists in older patients with ulcerative colitis: patient-level pooled analysis of data from randomized trials. Clin Gastroenterol Hepatol. 2020;19:939–46.PubMedCrossRef
49.
Lobatón T, Ferrante M, Rutgeerts P, Ballet V, Van Assche G, Vermeire S. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2015;42:441–51.PubMedCrossRef
50.
Desai A, Zator ZA, de Silva P, Nguyen DD, Korzenik J, Yajnik V, et al. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:309–15.PubMedCrossRef
51.
52.
de Jong ME, Smits LJT, van Ruijven B, den Broeder N, Russel MGVM, Römkens TEH, et al. Increased discontinuation rates of anti-TNF therapy in elderly inflammatory bowel disease patients. J Crohns Colitis. 2020;14:888–95.PubMedCrossRef
53.
Porcari S, Viola A, Orlando A, Privitera AC, Ferracane C, Cappello M, et al. Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). Persistence on anti-tumour necrosis factor therapy in older patients with inflammatory bowel disease compared with younger patients: data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). Drugs Aging. 2020;37:383–92.PubMedCrossRef
54.
55.
Cohen NA, Plevris N, Kopylov U, Grinman A, Ungar B, Yanai H, et al. Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study. United Eur Gastroenterol J. 2020;8:1076–85.CrossRef
56.
Weiss A, Trivedi C, Tyler Pernes T, Patel M, Khan NH. Efficacy of vedolizumab in a nationwide cohort of elderly inflammatory bowel disease patient. Gastroenteroloy. 2021;160(suppl):S346.CrossRef
57.
Shashi P, Gopalakrishnan D, Parikh MP, Shen B, Kochhar G. Efficacy and safety of vedolizumab in elderly patients with inflammatory bowel disease: a matched case-control study. Gastroenterol Rep (Oxf). 2019;8:306–11.CrossRef
58.
Attauabi M, Höglund C, Fassov J, Pedersen KB, Hansen HB, Wildt S, et al. Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases. Scand J Gastroenterol. 2021;56:1040–8.PubMedCrossRef
59.
Macaluso FS, Fries W, Renna S, Viola A, Muscianisi M, Cappello M, et al. Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Effectiveness and safety of vedolizumab in biologically naive patients: a real-world multi-centre study. United European Gastroenterol J. 2020;8:1045–55.PubMedPubMedCentralCrossRef
60.
Adar T, Faleck D, Sasidharan S, Cushing K, Borren NZ, Nalagatla N, et al. Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study. Aliment Pharmacol Ther. 2019;49:873–9.PubMedPubMedCentralCrossRef
61.
62.
Sands BE, Sandborn WJ, Panaccione R, O’Brien CD, Zhang H, Johanns J, et al. UNIFI Study Group. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381:1201–14.PubMedCrossRef
63.
Sandborn WJ, Panés J, D’Haens GR, Sands BE, Su C, Moscariello M, et al. Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials. Clin Gastroenterol Hepatol. 2019;17:1541–50.PubMedCrossRef
64.
Katz S, Feldstein R. Inflammatory bowel disease of the elderly: a wake-up call. Gastroenterol Hepatol (NY). 2008;4:337–47.PubMedCentral
65.
66.
Walton A, Paik J, Quebe A, Kannowski CL, Choong C, Anderson S, et al. Frequency of prescription claims for drugs that may interact with Janus kinase inhibitors among patients with rheumatoid arthritis in the US. Rheumatol Ther. 2021;8:599–607.PubMedPubMedCentralCrossRef
67.
Tse S, Dowty ME, Menon S, Gupta P, Krishnaswami S. Application of physiologically based pharmacokinetic modeling to predict drug exposure and support dosing recommendations for potential drug-drug interactions or in special populations: an example using Tofacitinib. J Clin Pharmacol. 2020;60:1617–28.PubMedPubMedCentralCrossRef
68.
Dewit O, Vanheuverzwyn R, Desager JP, Horsmans Y. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn’s disease. Aliment Pharmacol Ther. 2002;16:79–85.PubMedCrossRef
69.
Govani SM, Wiitala WL, Stidham RW, Saini SD, Hou JK, Feagins LA, et al. Age disparities in the use of steroid-sparing therapy for inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:1923–8.PubMedCrossRef
70.
Thomas TP. The complications of systemic corticosteroid therapy in the elderly. A retrospective study. Gerontology. 1984;30:60–5.PubMedCrossRef
71.
Singh A, Mahajan R, Kedia S, Dutta AK, Anand A, Bernstein CN, et al. Use of thiopurines in inflammatory bowel disease: an update. Intest Res. 2022;20:11–30.PubMedCrossRef
72.
Costantino G, Furfaro F, Belvedere A, Alibrandi A, Fries W. Thiopurine treatment in inflammatory bowel disease: response predictors, safety, and withdrawal in follow-up. J Crohns Colitis. 2012;6:588–96.PubMedCrossRef
73.
Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, et al. European Crohn’s and Colitis Organisation (ECCO). Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8:443–68.PubMedCrossRef
74.
Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of pneumonia among patients with inflammatory bowel disease. Am J Gastroenterol. 2013;108:240–8.PubMedPubMedCentralCrossRef
75.
Kantsø B, Simonsen J, Hoffmann S, Valentiner-Branth P, Petersen AM, Jess T. Inflammatory bowel disease patients are at increased risk of invasive pneumococcal disease: a nationwide Danish cohort study 1977–2013. Am J Gastroenterol. 2015;110:1582–7.PubMedCrossRef
76.
Brassard P, Bitton A, Suissa A, Sinyavskaya L, Patenaude V, Suissa S. Oral corticosteroids and the risk of serious infections in patients with elderly-onset inflammatory bowel diseases. Am J Gastroenterol. 2014;109:1795–802.PubMedCrossRef
77.
Cottone M, Kohn A, Daperno M, Armuzzi A, Guidi L, D’Inca R, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:30–5.PubMedCrossRef
78.
Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929–36.PubMedCrossRef
79.
Bossuyt P, Verhaegen J, Van Assche G, Rutgeerts P, Vermeire S. Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease. J Crohns Colitis. 2009;3:4–7.PubMedCrossRef
80.
Rodemann JF, Dubberke ER, Reske KA, da Seo H, Stone CD. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;3:339–41.CrossRef
81.
Issa M, Vijayapal A, Graham MB, Beaulieu DB, Otterson MF, Lundeen S, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:345–51.PubMedCrossRef
82.
Moshkowitz M, Ben-Baruch E, Kline Z, Shimoni Z, Niven M, Konikoff F. Risk factors for severity and relapse of pseudomembranous colitis in an elderly population. Colorectal Dis. 2007;9:173–7.PubMedCrossRef
83.
Dial S, Delaney JA, Schneider V, Suissa S. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by pre- scription for oral vancomycin therapy. CMAJ. 2006;175:745–8.PubMedPubMedCentralCrossRef
84.
Singh H, Nugent Z, Yu BN, Lix LM, Targownik LE, Bernstein CN. Higher incidence of Clostridium difficile infection among individuals with inflammatory bowel disease. Gastroenterology. 2017;153:430–8.PubMedCrossRef
85.
Law CC, Tariq R, Khanna S, Murthy S, McCurdy JD. Systematic review with meta-analysis: the impact of Clostridium difficile infection on the short- and long-term risks of colectomy in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45:1011–20.PubMedCrossRef
86.
Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther. 2009;30:253–64.PubMedCrossRef
87.
Balram B, Battat R, Al-Khoury A, D’Aoust J, Afif W, Bitton A, et al. Risk factors associated with Clostridium difficile infection in inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2019;13:27–38.PubMedCrossRef
88.
Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for Herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:1483–90.PubMedCrossRef
89.
Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of Herpes zoster among 108,604 patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:420–9.PubMedCrossRef
90.
Herfarth HH, Kappelman MD, Long MD, Isaacs KL. Use of methotrexate in the treatment of inflammatory bowel diseases. Inflamm Bowel Dis. 2016;22:224–33.PubMedCrossRef
91.
Khan N, Patel D, Trivedi C, Shah Y, Lichtenstein G, Lewis J, et al. Overall and comparative risk of Herpes zoster with pharmacotherapy for inflammatory bowel diseases: a nationwide cohort study. Clin Gastroenterol Hepatol. 2018;16:1919–27.PubMedCrossRef
92.
Winthrop KL, Melmed GY, Vermeire S, Long MD, Chan G, Pedersen RD, et al. Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis. 2018;24:2258–65.PubMedPubMedCentralCrossRef
93.
D’Amico F, Danese S, Peyrin-Biroulet L. Systematic review on inflammatory bowel disease patients with coronavirus disease 2019: it is time to take stock. Clin Gastroenterol Hepatol. 2020;18:2689–700.PubMedPubMedCentralCrossRef
94.
95.
Calafat M, González-Muñoza C, Fortuny M, Roig C, Calm A, Mombiela A, et al. Impact of immunosuppressants on SARS-CoV-2 infection in elderly patients with inflammatory bowel disease. Aging Clin Exp Res. 2021;33:2355–9.PubMedPubMedCentralCrossRef
96.
Peyrin-Biroulet C, D’Amico F, Peyrin-Biroulet L. Will COVID-19 infection be less severe in ulcerative colitis than in Crohn’s patients, due to a lower rate of smokers? J Crohns Colitis. 2020;14:1648.PubMedCrossRef
97.
Bernstein CN, Wajda A, Blanchard JF. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin Gastroenterol Hepatol. 2008;6:41–5.PubMedCrossRef
98.
Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103:2272–80.PubMedCrossRef
99.
McCurdy JD, Kuenzig ME, Smith G, Spruin S, Murthy SK, Carrier M, et al. Risk of venous thromboembolism after hospital discharge in patients with inflammatory bowel disease: a population-based study. Inflamm Bowel Dis. 2020;26:1761–8.PubMedCrossRef
100.
Øresland T, Bemelman WA, Sampietro GM, Spinelli A, Windsor A, Ferrante M, et al. European Crohn’s and Colitis Organisation (ECCO). European evidence based consensus on surgery for ulcerative colitis. J Crohns Colitis. 2015;9:4–25.PubMedCrossRef
101.
Sandborn WJ, Panés J, Sands BE, Reinisch W, Su C, Lawendy N, et al. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development program. Aliment Pharmacol Ther. 2019;50:1068–76.PubMedPubMedCentralCrossRef
102.
103.
104.
Annese V, Beaugerie L, Egan L, Biancone L, Bolling C, Brandts C, et al. ECCO. European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohns Colitis. 2015;9:945–65.PubMedCrossRef
105.
Kotlyar DS, Lewis JD, Beaugerie L, Tierney A, Brensinger CM, Gisbert JP, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015;13:847–58.PubMedCrossRef
106.
Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, Carbonnel F, Colombel JF, Dupas JL, Godeberge P, Hugot JP, Lémann M, Nahon S, et al. Cesame Study Group. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;141:1621-28.e1-5.PubMedCrossRef
107.
Bourrier A, Carrat F, Colombel JF, Bouvier AM, Abitbol V, Marteau P, et al. CESAME study group. Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Aliment Pharmacol Ther. 2016;43:252–61.PubMedCrossRef
108.
Beaugerie L, Carrat F, Colombel JF, Bouvier AM, Sokol H, Babouri A, et al. CESAME Study Group. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut. 2014;63:1416–23.PubMedCrossRef
109.
Gordillo J, Cabré E, Garcia-Planella E, Ricart E, Ber-Nieto Y, Márquez L, Rodríguez-Moranta F, et al. ENEIDA Project of the Spanish Working Group in Crohn’s Disease and Ulcerative Colitis (GETECCU). Thiopurine therapy reduces the incidence of colorectal neoplasia in patients with ulcerative colitis. Data from the ENEIDA Registry. J Crohns Colitis. 2015;9:1063–70.PubMedCrossRef
110.
Muller M, D’Amico F, Bonovas S, Danese S, Peyrin-Biroulet L. TNF inhibitors and risk of malignancy in patients with inflammatory bowel diseases: a systematic review. J Crohns Colitis. 2021;15:840–59.PubMedCrossRef
111.
Dahmus J, Rosario M, Clarke K. Risk of lymphoma associated with anti-TNF therapy in patients with inflammatory bowel disease: implications for therapy. Clin Exp Gastroenterol. 2020;13:339–50.PubMedPubMedCentralCrossRef
112.
Esse S, Mason KJ, Green AC, Warren RB. Melanoma risk in patients treated with biologic therapy for common inflammatory diseases: a systematic review and meta-analysis. JAMA Dermatol. 2020;156:787–94.PubMedCrossRef
113.
Wang JH, D’Arcy M, Barnes EL, Freedman ND, Engels EA, Song M. Associations of inflammatory bowel disease and subsequent cancers in a population-based study of older adults in the United States. JNCI Cancer Spectr. 2022;6:pkab096.CrossRef
114.
Vedamurthy A, Gangasani N, Ananthakrishnan AN. Vedolizumab or tumor necrosis factor antagonist use and risk of new or recurrent cancer in patients with inflammatory bowel disease with prior malignancy: a retrospective cohort study. Clin Gastroenterol Hepatol. 2020;S1542–3565(20):31396–403. https://​doi.​org/​10.​1016/​j.​cgh.​2020.​10.​007.CrossRef
115.
116.
Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2020;158:1554–73.PubMedCrossRef
117.
118.
Kuenzig ME, Manuel DG, Donelle J, Benchimol EI. Real world evidence of the association between medication and life expectancy in elderly inflammatory bowel disease: a population-based cohort study. BMC Gastroenterol. 2022;22:5.PubMedPubMedCentralCrossRef
119.
Schwartz J, Stein DJ, Lipcsey M, Li B, Feuerstein JD. High rates of mortality in geriatric patients admitted for inflammatory bowel disease management. J Clin Gastroenterol. 2022;56:e20–6.PubMedCrossRef
Metadata
Title
Ulcerative Colitis in Adulthood and in Older Patients: Same Disease, Same Outcome, Same Risks?
Authors
Walter Fries
Maria Giulia Demarzo
Giuseppe Navarra
Anna Viola
Publication date
01-06-2022
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 6/2022
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-022-00943-0

Other articles of this Issue 6/2022

Drugs & Aging 6/2022 Go to the issue

Correction

Correction to: The FORTA (Fit fOR The Aged) List 2021: Fourth Version of a Validated Clinical Aid for Improved Pharmacotherapy in Older Adults

Review Article

Depression in Patients with Parkinson’s Disease: Current Understanding of its Neurobiology and Implications for Treatment

Original Research Article

Hypotension Under Antihypertensive Treatment and Incident Hospitalizations of Nursing Home Residents

Current Opinion

Aspiring to Reasonableness in Accelerated Approval: Anticipating and Avoiding the Next Aducanumab

Review Article

Bladder Dysfunction in Older Adults: The Botulinum Toxin Option

Original Research Article

Psychotropic Drug Prescription in Nursing Homes During the COVID-19 Pandemic

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits